• GSK343: EZH2 Inhibition Meets TERT Biology

  2026-09-16

  GSK343 is a selective EZH2 inhibitor for dissecting H3K27me3-dependent gene repression in cancer models. This article connects its assay logic to new APEX2–TERT findings while clarifying what can—and cannot—be inferred about telomerase regulation.

• Novobiocin: From Target to Assay Decision

  2026-09-16

  Novobiocin is an aminocoumarin antibiotic whose antibacterial, antiparasitic, antiviral, and Hsp90-related activities require carefully matched assay designs. This guide translates target biology, concentration selection, and derivative-study evidence into practical decisions for reproducible research.

• Aclacinomycin A and the Hidden Logic of rDNA Damage

  2026-09-15

  Aclacinomycin A, or Aclarubicin, is more than a cytotoxic benchmark: its dual topoisomerase activity provides a strategic entry point for studying persistent ribosomal DNA damage, PML-nucleolar responses, apoptosis, and translational resistance mechanisms.

• Topological Stress, rDNA Lesions, and PML Compartments

  2026-09-15

  This study shows that topological stress and RNA polymerase I inhibition generate persistent lesions in ribosomal DNA, leading to PML-nucleolar associations that sequester damaged rDNA from active nucleoli. Its combination of targeted rDNA cleavage, repair-pathway perturbation, and imaging connects unresolved homologous-recombination intermediates with nuclear reorganization and cellular senescence.

• GLP-1R Promiscuity Revealed by FRET–cAMP Assays

  2026-09-14

  Chepurny et al. used high-throughput FRET assays, pharmacological antagonists, molecular modeling, and beta-cell experiments to show that glucagon can activate the GLP-1 receptor under pharmacological or locally concentrated conditions. The study also identifies receptor cross-talk relevant to interpreting GLP-1 receptor signaling research and designing multi-receptor metabolic therapeutics.

• Sumatriptan as an Anti-Inflammatory: Review Insights

  2026-09-14

  Ala et al.’s systematic review reframes sumatriptan from a migraine-focused 5-HT1B/1D agonist as a potential modulator of inflammatory signaling, including cytokines, nitric oxide, NF-κB, caspases, and CGRP release. Its practical value is hypothesis generation: the preclinical evidence supports mechanistic studies, but heterogeneous models and limited clinical validation prevent treating sumatriptan as an established general anti-inflammatory therapy.

• Paroxetine Mesylate Research Workflows

  2026-09-13

  Convert Paroxetine Mesylate pharmacology into reproducible SERT, enzyme-liability, kinase, and colorectal cancer experiments. This workflow separates high-affinity transporter activity from micromolar phenotypes, helping researchers choose better controls, exposure ranges, and orthogonal readouts.

• Baicalin Reactivates Visual Plasticity in Adult Amblyopia

  2026-09-12

  A 2026 NeuroImage study found that Baicalin restored ocular dominance plasticity and visual acuity in adult amblyopic mice when paired with reverse suturing. Optical imaging, electrophysiology, molecular measurements, and muscimol blockade linked the effect to reduced GABAergic inhibition and perineuronal-net expression in primary visual cortex.

• miRNA–mRNA Control of Juvenile Hormone Biosynthesis

  2026-09-11

  Li et al. identify coordinated miRNA–mRNA modules that release juvenile hormone synthesis genes from post-transcriptional repression during locust vitellogenesis. Their results connect corpora allata gene regulation with vitellogenin production and ovarian development, providing a mechanistic framework for studying hormone-regulated development in insects.

• Aclacinomycin A and Persistent rDNA Damage

  2026-09-11

  Aclacinomycin A, also known as Aclarubicin, offers translational researchers a mechanistically rich way to connect dual topoisomerase inhibition with DNA damage, nucleolar stress, apoptosis, and proteasome biology. This article places the compound within emerging research on persistent ribosomal DNA lesions and PML-nucleolar compartment formation while outlining a disciplined validation strategy.

• Stattic and the Translational Logic of STAT3 Inhibition

  2026-09-10

  STAT3 is more than a signaling node: it is a decision point linking inflammatory cues, tumor-cell survival, hypoxia adaptation, and treatment response. This thought-leadership analysis examines how Stattic, a small-molecule STAT3 inhibitor, can support mechanistic cancer biology, radiosensitization studies, and translational assay design. It also uses recent STING-STAT3-autophagy findings in psoriasis to clarify where pathway biology is transferable, where evidence remains preclinical, and how researchers can build more rigorous validation strategies.

• 7-dehydro Cholesterol: From Sterol Flux to Translation

  2026-09-10

  7-dehydro Cholesterol is more than a cholesterol-biosynthesis intermediate: it is a controllable probe of DHCR7 activity, vitamin D3 formation, UVB response, oxidative lipid stress, and sterol-linked immunity. This article examines how recent dhcr7 knockout grass carp data expand the translational value of 7-dehydrocholesterol while defining the limits of cross-species and substrate-versus-genetic interpretation.

• Dabigatran: Mechanism, Assays, and Clinical Use

  2026-09-09

  Dabigatran is a reversible direct thrombin inhibitor used in anticoagulation research and in clinical Pradaxa therapy. Its measurable thrombin inhibition, active acylglucuronide metabolite, renal dosing constraints, and assay-specific limitations make it useful for controlled coagulation studies.

• CCK-8 for Nanoparticle Cancer Research

  2026-09-09

  Discover how cck8 transforms metabolic signal into a carefully controlled cell viability measurement for nanoparticle oncology studies. This guide uses sorafenib-loaded prostate cancer nanoparticles to explain assay design, interference controls, and interpretation beyond a simple viability percentage.

• Tubastatin A After Cardiac Arrest: Porcine Evidence

  2026-09-08

  A 2025 porcine study found that post-resuscitation Tubastatin A treatment reduced myocardial dysfunction, cardiac injury biomarkers, and molecular signals associated with GSDME-mediated pyroptosis and MLKL-mediated necroptosis. The work provides large-animal evidence for a potentially targeted HDAC6 inhibitor strategy, while its short follow-up and correlative mechanism leave important translational questions unresolved.

8068 records 1/538 page Next 12345 下5页 Last page